SwePub
Tyck till om SwePub Sök här!
Sök i LIBRIS databas

  Extended search

WFRF:(Zurakowski A)
 

Search: WFRF:(Zurakowski A) > University of Gothenburg > Six months versus 1...

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Six months versus 12 months dual antiplatelet therapy after drug-eluting stent implantation in ST-elevation myocardial infarction (DAPT-STEMI): randomised, multicentre, non-inferiority trial

Kedhi, E. (author)
Fabris, E. (author)
van der Ent, M. (author)
show more...
Buszman, P. (author)
von Birgelen, C. (author)
Roolvink, V. (author)
Zurakowski, A. (author)
Schotborgh, C. E. (author)
Hoorntje, J. C. A. (author)
Eek, C. H. (author)
Cook, S. (author)
Togni, M. (author)
Meuwissen, M. (author)
van Royen, N. (author)
van Vliet, R. (author)
Wedel, Hans (author)
Gothenburg University,Göteborgs universitet,Institutionen för medicin,Institute of Medicine
Delewi, R. (author)
Zijlstra, F. (author)
show less...
 (creator_code:org_t)
2018-10-02
2018
English.
In: Bmj-British Medical Journal. - : BMJ. - 1756-1833. ; 363
  • Journal article (peer-reviewed)
Abstract Subject headings
Close  
  • OBJECTIVE To show that limiting dual antiplatelet therapy (DAPT) to six months in patients with event-free ST-elevation myocardial infarction (STEMI) results in a non-inferior clinical outcome versus DAPT for 12 months. Patients with STEMI treated with primary percutaneous coronary intervention (PCI) and second generation zotarolimus-eluting stent. Patients with STEMI aged 18 to 85 that underwent a primary PCI with the implantation of second generation drug-eluting stents were enrolled in the trial. Patients that were event-free at six months after primary PCI were randomised at this time point. Patients that were taking DAPT and were event-free at six months were randomised 1:1 to single antiplatelet therapy (SAPT) (ie, aspirin only) or to DAPT for an additional six months. All patients that were randomised were then followed for another 18 months (ie, 24 months after the primary PCI). The primary endpoint was a composite of all cause mortality, any myocardial infarction, any revascularisation, stroke, and thrombolysis in myocardial infarction major bleeding at 18 months after randomisation. A total of 1100 patients were enrolled in the trial between 19 December 2011 and 30 June 2015. 870 were randomised: 432 to SAPT versus 438 to DAPT. The primary endpoint occurred in 4.8% of patients receiving SAPT versus 6.6% of patients receiving DAPT (hazard ratio 0.73, 95% confidence interval 0.41 to 1.27, P=0.26). Non-inferiority was met (P=0.004 for non-inferiority), as the upper 95% confidence interval of 1.27 was smaller than the prespecified non-inferiority margin of 1.66. DAPT to six months was non-inferior to DAPT for 12 months in patients with event-free STEMI at six months after primary PCI with second generation drug-eluting stents.

Subject headings

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Kardiologi (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Cardiac and Cardiovascular Systems (hsv//eng)

Keyword

percutaneous coronary intervention
optical coherence tomography
network metaanalysis
atrial-fibrillation
clinical-trial
clopidogrel
thrombosis
insights
impact
angiography
General & Internal Medicine
esebro jh
1987
circulation
v76
p142

Publication and Content Type

ref (subject category)
art (subject category)

Find in a library

To the university's database

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view